Metabolomic screening of phenolic compounds originating from edible plants strongly inhibiting pancreatic lipase in vitro

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22330%2F23%3A43928152" target="_blank" >RIV/60461373:22330/23:43928152 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Metabolomic screening of phenolic compounds originating from edible plants strongly inhibiting pancreatic lipase in vitro

Popis výsledku v původním jazyce

According to the latest information by the World Health Organization (WHO, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight, last accessed 30/6/2023), 39% of adults and 18% of children and adolescents are overweight or obese, which is a major risk factor for a metabolic syndrome development. This highlights the urgent need to investigate strategies to control obesity. Among the available approaches [1], utilizing natural bioactive compounds such as polyphenols to inhibit the activity of pancreatic lipase (PNLIP) (EC 3.1.1.3) has been promising [2]. PNLIP hydrolyses triacylglycerols to monoacylglycerols and free fatty acids in a high rate, up to 70%. Considering that dietary fats are mostly constituted of triacylglycerols and their contribution to energy intake, inhibiting PNLIP may be an effective strategy in reducing the synthesis of adipose tissue preventing from excessive fat deposition [3]. Importantly, PNLIP inhibitors have been identified in edible plants widely consumed around the globe indicating potential candidates for the production of “nutraceuticals”. Nutraceuticals encompass a wide range of dietary sources including dietary supplements and processed foods with a high abundance in phenolic bioactive compounds with reported antioxidant, cardiovascular protective, anti-inflammatory properties and PNLIP inhibitory effects [4].In this study, to identify edible sources with potential nutraceutical applications, 145 dietary plants were screened in terms of their in vitro PNLIP inhibitory effect. Both aqueous and non-polar extracts were tested, aiming to isolate different bioactive compounds in each occasion. After performing a high throughput screening of these crude extracts, a cut-off inhibitory level was set (70%) and only extracts exceeding this level were further analysed using an ultra-high-performance liquid chromatography hybrid quadrupole time-of-flight mass spectrometry (UHPLC-q-TOF-MS) system. A metabolomic workflow based on suspect screening was applied and bioactive compounds were tentatively identified highlighting their potential as PNLIP inhibitors.References1. Müller TD, Blüher M, Tschöp MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21:201–223. https://doi.org/10.1038/s41573-021-00337-82. Kumar A, Chauhan S (2021) Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci 271:119115. https://doi.org/https://doi.org/10.1016/j.lfs.2021.1191153. Liu T-T, Liu X-T, Chen Q-X, Shi Y (2020) Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother 128:110314. https://doi.org/https://doi.org/10.1016/j.biopha.2020.1103144. Ammendola S, Scotto d’Abusco A (2022) Nutraceuticals and the Network of Obesity Modulators. Nutrients 14:5099

Název v anglickém jazyce

Metabolomic screening of phenolic compounds originating from edible plants strongly inhibiting pancreatic lipase in vitro

Popis výsledku anglicky

According to the latest information by the World Health Organization (WHO, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight, last accessed 30/6/2023), 39% of adults and 18% of children and adolescents are overweight or obese, which is a major risk factor for a metabolic syndrome development. This highlights the urgent need to investigate strategies to control obesity. Among the available approaches [1], utilizing natural bioactive compounds such as polyphenols to inhibit the activity of pancreatic lipase (PNLIP) (EC 3.1.1.3) has been promising [2]. PNLIP hydrolyses triacylglycerols to monoacylglycerols and free fatty acids in a high rate, up to 70%. Considering that dietary fats are mostly constituted of triacylglycerols and their contribution to energy intake, inhibiting PNLIP may be an effective strategy in reducing the synthesis of adipose tissue preventing from excessive fat deposition [3]. Importantly, PNLIP inhibitors have been identified in edible plants widely consumed around the globe indicating potential candidates for the production of “nutraceuticals”. Nutraceuticals encompass a wide range of dietary sources including dietary supplements and processed foods with a high abundance in phenolic bioactive compounds with reported antioxidant, cardiovascular protective, anti-inflammatory properties and PNLIP inhibitory effects [4].In this study, to identify edible sources with potential nutraceutical applications, 145 dietary plants were screened in terms of their in vitro PNLIP inhibitory effect. Both aqueous and non-polar extracts were tested, aiming to isolate different bioactive compounds in each occasion. After performing a high throughput screening of these crude extracts, a cut-off inhibitory level was set (70%) and only extracts exceeding this level were further analysed using an ultra-high-performance liquid chromatography hybrid quadrupole time-of-flight mass spectrometry (UHPLC-q-TOF-MS) system. A metabolomic workflow based on suspect screening was applied and bioactive compounds were tentatively identified highlighting their potential as PNLIP inhibitors.References1. Müller TD, Blüher M, Tschöp MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21:201–223. https://doi.org/10.1038/s41573-021-00337-82. Kumar A, Chauhan S (2021) Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci 271:119115. https://doi.org/https://doi.org/10.1016/j.lfs.2021.1191153. Liu T-T, Liu X-T, Chen Q-X, Shi Y (2020) Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother 128:110314. https://doi.org/https://doi.org/10.1016/j.biopha.2020.1103144. Ammendola S, Scotto d’Abusco A (2022) Nutraceuticals and the Network of Obesity Modulators. Nutrients 14:5099

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30308 - Nutrition, Dietetics

Projekt

—

Návaznosti

—

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů